ICP-192 not checked

Beijing InnoCare Pharma Tech Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Intrahepatic Cholangiocarcinoma (ICC)
Main trialPhase 2
“This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy”In the company’s words, NCT05678270 on ClinicalTrials.gov

Other drugs for Intrahepatic Cholangiocarcinoma (ICC)

All 45 drugs for Intrahepatic Cholangiocarcinoma (ICC)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Recruiting May 2026 A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Phase 2Unknown 31 Dec 2023 A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
Phase 2Unknown 31 Dec 2024 An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
Phase 1/2Unknown 30 Nov 2023 A Study of ICP-192 in Patients With Advanced Solid Tumors
Phase 1/2Unknown 31 Dec 2024 Clinical Study of ICP-192 in Solid Tumors Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ICP-192

Following is part of Solo: you see every change to ICP-192 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in